Live
- Chittoor police crack down on drunk driving with 963 cases
- Vision document historical, says Keshav
- YSRCP to boycott elections to WUAs
- Farmers led by YSRCP leaders stage protest against graft
- MLA Dhanpal reminds Cong of promise of gold for brides
- Dy CM Pawan hails Swarna Andhra@2047 vision document
- Ensure success of Mathematic Talent exam
- Atchannaidu expresses concern over fall in tomato price
- Goshamahal Welfare Assn petition Collector seeking withdrawal of Osmania Hosp plans at stadium
- Indiramma Housing scheme 4L applications received in RR dist
Optimus Pharma gets DCGI nod for Covid drug
Optimus Pharma gets DCGI nod for Covid drug
City-based Optimus Pharma on Tuesday received DCGI nod for conducting phase III clinical trials for orally administered Molnupiravir capsules on patients with mild and moderate Covid-19.
Hyderabad: City-based Optimus Pharma on Tuesday received DCGI nod for conducting phase III clinical trials for orally administered Molnupiravir capsules on patients with mild and moderate Covid-19. With severe shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced.
Optimus pharma said having internally developed the active pharmaceutical ingredient (API) and the formulations for the product, it had filed for clinical trials with the DCGI.
"Optimus is all geared to immediately begin clinical trials on Molnupiravir on Covid -19 patients in India. The clinical trial will let us know the efficacy of this molecule on Covid patients," CMD Dr D Srinivas Reddy said.
